Clinical Trial Update: Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and efficacy of OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells for refractory Type 2 Diabetes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OCN19-overexpressed human umbilical cord-derived mesenchymal stem cells

Snippet

Sponsor: Lu jin ，MD | Conditions: Diabetes, Type 2 Diabetes | Phase 2 | Status: RECRUITING